Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $52 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AMLX Hot Sheet
Price: $29.40 +0.68%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Baird analyst Joel Beatty raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $52.00 (from $28.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
- Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
- First Industrial Realty Trust (FR) PT Lowered to $62 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
